These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17086220)

  • 21. [Therapeutic options and controversies in the management of prostate cancer].
    Peyromaure M; Thiounn N
    Rev Prat; 2003 Dec; 53(20):2263-7. PubMed ID: 15018081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].
    Batman E; de Wit R
    Ned Tijdschr Geneeskd; 2005 Oct; 149(44):2442-5. PubMed ID: 16285357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 24. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.
    Oh WK
    J Urol; 2003 Dec; 170(6 Pt 2):S28-32; discussion S33-4. PubMed ID: 14610407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of hormone-refractory prostate cancer].
    Heidenreich A
    Urologe A; 2005 Dec; 44(12):1481-94; quiz 1495. PubMed ID: 16311709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
    Di Lorenzo G; Autorino R; Perdonà S; De Laurentiis M; D'Armiento M; Cancello G; Mirone V; Imbimbo C; Longo N; Altieri V; Tortora G; Figg WD; De Placido S
    Eur Urol; 2007 Oct; 52(4):1020-7. PubMed ID: 17360103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
    Miyoshi Y; Uemura H; Nakamura M; Hasumi H; Sugiura S; Makiyama K; Nakaigawa N; Kishida T; Ogawa T; Yao M; Kubota Y
    Int J Clin Oncol; 2005 Jun; 10(3):182-6. PubMed ID: 15990966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
    Fischel JL; Ciccolini J; Formento P; Ferrero JM; Milano G
    Anticancer Drugs; 2006 Aug; 17(7):807-13. PubMed ID: 16926630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
    Ansari J; Hussain SA; Zarkar A; Tanguay JS; Bliss J; Glaholm J
    Oncol Rep; 2008 Oct; 20(4):891-6. PubMed ID: 18813832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].
    Wolff JM
    Onkologie; 2003 Dec; 26 Suppl 7():37-40. PubMed ID: 14716141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma].
    Miller K; Becker K; Finke F; Geiges G; Göckel-Beining B; Hossfeld DK; Miller K; Osieka R; Rüssel C; Tesch H; Weissbach L; Wirth M; Wolff JM
    Aktuelle Urol; 2006 May; 37(3):201-4. PubMed ID: 16733822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
    Joensuu TK
    Urol Int; 2008; 80(4):448-50. PubMed ID: 18587260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of hormone resistant prostate cancer.
    Fosså SD
    Acta Urol Belg; 1994 Apr; 62(1):73-6. PubMed ID: 7515211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.
    Brubaker KD; Brown LG; Vessella RL; Corey E
    BMC Cancer; 2006 Jan; 6():15. PubMed ID: 16417633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormone-refractory prostate cancer: an evolving standard of care.
    Small EJ; Reese DM; Vogelzang NJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):61-7. PubMed ID: 10604272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of treatment for patients with metastatic prostate cancer.
    Higano CS
    Can J Urol; 2005 Jun; 12 Suppl 2():38-41. PubMed ID: 16018832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.